Bristol-Myers Squibb Co
CELG_r0.090USD
-0.010-11.24%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Bristol-Myers Squibb Co Company
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Bristol-Myers Squibb Co Info
Ticker SymbolCELG_r
Company nameBristol-Myers Squibb Co
IPO dateMar 17, 1980
CEOBoerner (Christopher S)
Number of employees- -
Security typeRight
Fiscal year-end- -
AddressRoute 206 And Province Line Road
CityPRINCETON
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code08543
Phone16092524621
Websitehttps://www.bms.com
Ticker SymbolCELG_r
IPO dateMar 17, 1980
CEOBoerner (Christopher S)
Company Executives of Bristol-Myers Squibb Co
Name
Name/Position
Position
Shareholding
Change
Mr. Peter J. (Pete) Arduini
Mr. Peter J. (Pete) Arduini
Independent Director
Independent Director
--
--
Mr. Theodore R. Samuels, II
Mr. Theodore R. Samuels, II
Lead Independent Director
Lead Independent Director
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. David V. Elkins
Mr. David V. Elkins
Executive Vice President, Chief Financial Officer, Member of the Leadership Team
Executive Vice President, Chief Financial Officer, Member of the Leadership Team
--
--
Ms. Paula A. Price
Ms. Paula A. Price
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter J. (Pete) Arduini
Mr. Peter J. (Pete) Arduini
Independent Director
Independent Director
--
--
Mr. Theodore R. Samuels, II
Mr. Theodore R. Samuels, II
Lead Independent Director
Lead Independent Director
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
32
423.55K
0.00%
--
2025Q3
33
423.55K
0.00%
-91.51K
2025Q2
34
515.06K
0.00%
+32.24K
2025Q1
32
482.82K
0.00%
-636.30K
2024Q4
32
943.61K
0.00%
+342.07K
2024Q3
31
601.53K
0.00%
+90.03K
2024Q2
30
511.50K
0.00%
+113.76K
2024Q1
32
397.74K
0.00%
-298.70K
2023Q4
30
495.62K
0.00%
-40.30K
2023Q3
30
535.93K
0.00%
-7.05K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
International Assets Investment Management, LLC
175.00
0%
+175.00
--
Jun 30, 2024
Transcend Capital Advisors, LLC
109.17K
0%
--
--
Sep 30, 2025
Davenport Asset Management
83.97K
0%
--
--
Sep 30, 2025
BofA Global Research (US)
51.83K
0%
--
--
Sep 30, 2025
Purkiss Capital Advisors LLC
26.45K
0%
--
--
Sep 30, 2025
Two Sigma Investments, LP
12.74K
0%
-9.25K
-42.06%
Sep 30, 2025
MainStreet Advisors
20.00K
0%
--
--
Sep 30, 2025
Watts Gwilliam & Co LLC
20.00K
0%
--
--
Sep 30, 2025
Private Advisor Group LLC
15.00K
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
